Partial NephrectomyHEMOSTA-PNNCT07232927

Evaluation of Hemostatic Agents in Partial Nephrectomy

A study testing Standard Parenchymal Suturing, Suturing with FloSeal® and Suturing with Surgicel® in people with Partial Nephrectomy and Hemostatic Agents, run by Ankara University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 years and older
Conditions the study is for: Partial Nephrectomy, Hemostatic Agents, Localized Renal Cell Carcinoma
What is being tested?: Standard Parenchymal Suturing, Suturing with FloSeal® and Suturing with Surgicel®
Type of treatment: Surgery or procedure
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 150 participants
Where: 1 siteTurkey (Türkiye)
Study dates: 2 Jan 2023to 27 Dec 2024
Phase: Interventional
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Patients aged 18 years or older.
Diagnosed with localized renal mass (clinical stage T1a-T1b) suitable for partial nephrectomy.
Adequate preoperative renal function to undergo surgery.
Signed informed consent obtained prior to study enrollment.
Undergoing open, laparoscopic, or robotic partial nephrectomy performed by the same experienced surgeon.

Who cannot join

Patients with solitary kidney or bilateral renal tumors.
History of previous renal surgery on the same kidney.
Evidence of metastatic disease or locally advanced (≥T2) renal tumors.
Coagulopathy, bleeding disorders, or ongoing anticoagulant therapy that cannot be discontinued.
Active urinary tract infection or systemic infection.
Known allergy or hypersensitivity to gelatin or oxidized cellulose components.
Patients who decline participation or withdraw consent.
Incomplete perioperative data or loss to follow-up.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site

Ankara University Faculty of Medicine, Department of Urology
Ankara, Ankara, 06590

Other trials in Turkey (Türkiye)

About this study

Official title: Evaluation of Hemostatic Agents in Partial Nephrectomy: A Prospective Randomized Trial

This prospective randomized study aims to evaluate the effect of adjunctive hemostatic agents (FloSeal® and Surgicel®) on perioperative outcomes in patients undergoing partial nephrectomy for localized renal tumors. A total of 150 patients were randomized into three groups: standard parenchymal suturing (Group A), suturing with FloSeal® (Group B), and suturing with Surgicel® (Group C). The study primarily investigates whether hemostatic agents reduce postoperative hemorrhage, urinary leakage, and positive surgical margin rates. Secondary outcomes include renal function change, operative and ischemia times, estimated blood loss, and hospital stay. All surgeries were performed by a single experienced surgeon at Ankara University Urology Department between January 2023 and December 2024.

Read the detailed description

Partial nephrectomy (PN) is the standard surgical treatment for localized renal tumors, providing oncologic efficacy comparable to radical nephrectomy while preserving renal function. Despite technological advances, hemorrhage and urinary leakage remain major perioperative challenges. Various hemostatic agents have been introduced to improve intraoperative hemostasis and collecting system closure, including gelatin-thrombin matrices (FloSeal®) and oxidized regenerated cellulose (Surgicel®). However, the true clinical value of these agents remains controversial due to limited high-quality evidence.

This prospective, randomized, single-center trial was conducted at Ankara University Faculty of Medicine, Department of Urology. The study enrolled 150 patients with localized renal masses (clinical stage T1a-T1b) scheduled for partial nephrectomy between January 2023 and December 2024. Patients were randomized equally into three groups: Group A (suturing only), Group B (suturing with FloSeal®), and Group C (suturing with Surgicel®). All surgeries were performed by a single experienced urologic surgeon using open, laparoscopic, or robotic approaches according to tumor complexity and patient preference.

The primary endpoints were the incidence of clinically significant postoperative hemorrhage requiring transfusion, urinary leakage/fistula, and oncologic safety assessed by positive surgical margins. Secondary outcomes included operative and ischemia times, estimated blood loss, postoperative renal function, and length of hospital stay. Statistical analyses included ANOVA, chi-square, logistic regression, and ROC curve analyses to identify predictors of perioperative complications and surgical margin positivity.

This study provides prospective evidence that adjunctive hemostatic agents do not significantly reduce postoperative hemorrhage or urinary leakage rates and do not influence oncologic safety. Perioperative outcomes are mainly determined by tumor and surgical factors rather than the use of hemostatic materials.

Conditions: Partial Nephrectomy, Hemostatic Agents, Localized Renal Cell Carcinoma
Being tested: Standard Parenchymal Suturing, Suturing with FloSeal®, Suturing with Surgicel®
Keywords: Partial nephrectomy, Renal cell carcinoma, Hemostatic agents, FloSeal, Surgicel, Hemorrhage, Urinary leakage
Medical subject headings: Carcinoma, Renal Cell, Hemorrhage

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Standard Parenchymal SuturingProcedure or surgery
Standard parenchymal suturing technique performed during partial nephrectomy without the use of adjunctive hemostatic materials. Serves as the control arm in the study.
Suturing with FloSeal®Procedure or surgery
Partial nephrectomy performed with parenchymal suturing combined with gelatin-thrombin matrix (FloSeal®) as an adjunctive hemostatic agent.
Suturing with Surgicel®Procedure or surgery
Partial nephrectomy performed with parenchymal suturing combined with oxidized regenerated cellulose (Surgicel®) as an adjunctive hemostatic agent.

Study groups in NCT07232927
Study group	Role	What they receive
Group A - Suturing Only	Active comparator	Standard parenchymal suturing technique without use of adjunctive hemostatic material. Receives: Procedure: Standard Parenchymal Suturing
Group B - Suturing + FloSeal®	Experimental	Parenchymal suturing performed with adjunctive application of gelatin-thrombin matrix (FloSeal®). Receives: Procedure: Suturing with FloSeal®
Group C - Suturing + Surgicel®	Experimental	Parenchymal suturing performed with adjunctive use of oxidized regenerated cellulose (Surgicel®). Receives: Procedure: Suturing with Surgicel®

What is being measured

The primary outcome is the main question the study is designed to answer.

Incidence of clinically significant postoperative hemorrhage requiring blood transfusion
Presence of postoperative bleeding requiring blood transfusion, radiologic, or surgical intervention, recorded according to standardized clinical criteria.
Measured: From postoperative Day 0 through postoperative Day 30
Incidence of postoperative urinary leakage or fistula
Detection of urinary leakage based on drain creatinine measurement or radiologic evidence of fistula following partial nephrectomy.
Measured: From postoperative Day 0 through postoperative Day 30
Rate of positive surgical margins
Pathologic assessment of surgical margins on resected tumor specimens to evaluate oncologic safety.
Measured: At pathological assessment (Day of surgery)

Secondary outcomes (4)

Mean operative time and warm ischemia time
Duration of surgery (skin-to-skin time) and warm ischemia time measured intraoperatively in minutes.
Measured: Intraoperative (Day of surgery)
Estimated blood loss during surgery
Total blood loss recorded by anesthesia team and surgical staff.
Measured: Intraoperative (Day of surgery)
Change in postoperative renal function (serum creatinine and eGFR)
Comparison of preoperative and postoperative serum creatinine and eGFR values to assess renal function preservation.
Measured: Preoperative (1 day before surgery) and postoperative Day 30
Postoperative hospital stay
Number of days from operation until hospital discharge.
Measured: From postoperative Day 0 until discharge, assessed for up to 30 days.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

2 Jan 202327 Dec 2024

First posted18 Nov 2025
Study start2 Jan 2023
Primary completion1 Dec 2024
Study completion27 Dec 2024

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (22)Papers the sponsor has linked to this study.
Other trials for Partial NephrectomyStudies of the same condition, open and under way.
More trials run by Ankara UniversityThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Model description: A prospective, randomized, single-center, three-arm, parallel assignment clinical trial comparing standard parenchymal suturing (Group A), suturing with FloSeal® (Group B), and suturing with Surgicel® (Group C) during partial nephrectomy for localized renal tumors.
Masking: None (open label)
Enrolment: 150 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07232927
Sponsor's protocol ID: İ3-191-20
Acronym: HEMOSTA-PN
Status last verified: Nov 2025
First submitted: 13 Nov 2025
Last updated: 18 Nov 2025
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Undecided

Publications

Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, Russo P, Uzzo RG; Practice Guidelines Committee of the American Urological Association. Guideline for management of the clinical T1 renal mass. J Urol. 2009 Oct;182(4):1271-9. doi: 10.1016/j.juro.2009.07.004. Epub 2009 Aug 14. No abstract available.
PubMed 19683266
Di Maida F, Campi R, Lane BR, De Cobelli O, Sanguedolce F, Hatzichristodoulou G, Antonelli A, Grosso AA, Noyes S, Rodriguez-Faba O, Keeley FX, Langenhuijsen J, Musi G, Klatte T, Roscigno M, Akdogan B, Furlan M, Simeone C, Karakoyunlu N, Marszalek M, Capitanio U, Volpe A, Brookman-May S, Gschwend JE, Smaldone MC, Uzzo RG, Kutikov A, Minervini A, Sib International Consortium. Predictors of Positive Surgical Margins after Robot-Assisted Partial Nephrectomy for Localized Renal Tumors: Insights from a Large Multicenter International Prospective Observational Project (The Surface-Intermediate-Base Margin Score Consortium). J Clin Med. 2022 Mar 23;11(7):1765. doi: 10.3390/jcm11071765.
PubMed 35407375
Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, Fernandez-Pello S, Giles RH, Hofmann F, Hora M, Klatte T, Kuusk T, Lam TB, Marconi L, Powles T, Tahbaz R, Volpe A, Bex A. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022 Oct;82(4):399-410. doi: 10.1016/j.eururo.2022.03.006. Epub 2022 Mar 26.
PubMed 35346519
Zargar H, Khalifeh A, Autorino R, Akca O, Brandao LF, Laydner H, Krishnan J, Samarasekera D, Haber GP, Stein RJ, Kaouk JH. Urine leak in minimally invasive partial nephrectomy: analysis of risk factors and role of intraoperative ureteral catheterization. Int Braz J Urol. 2014 Nov-Dec;40(6):763-71. doi: 10.1590/S1677-5538.IBJU.2014.06.07.
PubMed 25615258
Erlich T, Abu-Ghanem Y, Ramon J, Mor Y, Rosenzweig B, Dotan Z. Postoperative Urinary Leakage Following Partial Nephrectomy for Renal Mass: Risk Factors and a Proposed Algorithm for the Diagnosis and Management. Scand J Surg. 2017 Jun;106(2):139-144. doi: 10.1177/1457496916659225. Epub 2016 Jul 18.
PubMed 27431979
Kola O, Smigelski M, Nagpal S, Gogaj R, Taneja SS, Wysock JS, Huang WC. Urine leak and vascular complications following robotic partial nephrectomy: a contemporary single-center experience. J Robot Surg. 2024 Oct 29;18(1):387. doi: 10.1007/s11701-024-02096-1.
PubMed 39470887
Maurice MJ, Ramirez D, Kara O, Malkoc E, Nelson RJ, Caputo PA, Kaouk JH. Omission of Hemostatic Agents During Robotic Partial Nephrectomy Does Not Increase Postoperative Bleeding Risk. J Endourol. 2016 Aug;30(8):877-83. doi: 10.1089/end.2016.0192.
PubMed 27279548
Basu S, Khan IA, Das RK, Dey RK, Khan D, Agarwal V. RENAL nephrometry score: Predicting perioperative outcomes following open partial nephrectomy. Urol Ann. 2019 Apr-Jun;11(2):187-192. doi: 10.4103/UA.UA_93_18.
PubMed 31040606
Abu-Ghanem Y, Dotan Z, Kaver I, Zilberman DE, Ramon J. The use of Haemostatic Agents does not impact the rate of hemorrhagic complications in patients undergoing partial nephrectomy for renal masses. Sci Rep. 2016 Aug 30;6:32376. doi: 10.1038/srep32376.
PubMed 27572274
Aykan S, Temiz MZ, Ulus I, Yilmaz M, Gonultas S, Suzan S, Semercioz A, Muslumanoglu AY. The Use of Three Different Hemostatic Agents during Laparoscopic Partial Nephrectomy: A Comparison of Surgical and Early Renal Functional Outcomes. Eurasian J Med. 2019 Jun;51(2):160-164. doi: 10.5152/eurasianjmed.2018.18293.
PubMed 31258357
Veccia A, Autorino R. Is there a relation between preserved renal function and oncological outcomes in patients undergoing partial nephrectomy for renal cell carcinoma? Ann Transl Med. 2018 Nov;6(Suppl 1):S88. doi: 10.21037/atm.2018.11.01. No abstract available.
PubMed 30613663
Tonyali S, Koni A, Yazici S, Bilen CY. The Safety and Efficacy of Adjuvant Hemostatic Agents During Laparoscopic Nephron-Sparing Surgery: Comparison of Tachosil and Floseal Versus No Hemostatic Agents. Urol J. 2017 Jan 23;15(1):21-25. doi: 10.22037/uj.v0i0.4090.
PubMed 29277887
Richter F, Schnorr D, Deger S, Trk I, Roigas J, Wille A, Loening SA. Improvement of hemostasis in open and laparoscopically performed partial nephrectomy using a gelatin matrix-thrombin tissue sealant (FloSeal). Urology. 2003 Jan;61(1):73-7. doi: 10.1016/s0090-4295(02)02143-x.
PubMed 12559270
Gill IS, Ramani AP, Spaliviero M, Xu M, Finelli A, Kaouk JH, Desai MM. Improved hemostasis during laparoscopic partial nephrectomy using gelatin matrix thrombin sealant. Urology. 2005 Mar;65(3):463-6. doi: 10.1016/j.urology.2004.10.030.
PubMed 15780356
Carrion DM, Y Gregorio SA, Rivas JG, Bazan AA, Sebastian JD, Martinez-Pineiro L. The role of hemostatic agents in preventing complications in laparoscopic partial nephrectomy. Cent European J Urol. 2017;70(4):362-367. doi: 10.5173/ceju.2017.1432. Epub 2017 Oct 17.
PubMed 29410886

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruitingObservational study
A Study to Understand the Utility of the Force Feedback Instruments in Robotic Procedures Using da Vinci 5 Robot
Hernia, Inguinal, Hernia, Ventral
Active, not recruitingObservational study
Multimodal Prediction of Postoperative Prognosis After Partial Nephrectomy for Endophytic Renal Cell Carcinoma
Renal Cell Carcinoma, Kidney Neoplasms
Active, not recruitingObservational study
Analysis of Predictive Factors for Urinary Leakage After Partial Nephrectomy for Renal Hilum Tumors
Partial Nephrectomy, Renal Hilum Tumors
Recruiting
Prospective Study on the Safety and Efficacy of Robot-Assisted Laparoscopic Partial Nephrectomy With Renal Artery Off-Clamp in the Treatment of cT1 Renal Tumors
RCC, Renal Cell Cancer, Partial Nephrectomy
Recruiting
Robot-assisted Laparoscopic Partial Nephrectomy Via the Extraperitoneal Approach in the Prone Position Versus the Lateral Position
Renal Tumor, Prone Position

All Partial Nephrectomy trials

Study at a glance

From the registry record, last updated by the sponsor on 18 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Evaluation of Hemostatic Agents in Partial Nephrectomy: A Prospective Randomized Trial
ClinicalTrials.gov ID: NCT07232927
Acronym / sponsor ID: HEMOSTA-PN / İ3-191-20
Conditions: Partial Nephrectomy, Hemostatic Agents, Localized Renal Cell Carcinoma
Keywords: Partial nephrectomy, Renal cell carcinoma, Hemostatic agents, FloSeal, Surgicel, Hemorrhage, Urinary leakage
Study type: Interventional
Recruitment status: Completed
Enrolment: 150 participants (actual)
Lead sponsor: Ankara UniversityUniversity, hospital or other
Study start: 2 Jan 2023 (actual)
Primary completion: 1 Dec 2024 (actual)
Study completion: 27 Dec 2024 (actual)
First posted: 18 Nov 2025 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 3
Model description: A prospective, randomized, single-center, three-arm, parallel assignment clinical trial comparing standard parenchymal suturing (Group A), suturing with FloSeal® (Group B), and suturing with Surgicel® (Group C) during partial nephrectomy for localized renal tumors.

Arm	Type	Receives
Group A - Suturing Only	Active comparator	Procedure: Standard Parenchymal SuturingStandard parenchymal suturing technique without use of adjunctive hemostatic material.
Group B - Suturing + FloSeal®	Experimental	Procedure: Suturing with FloSeal®Parenchymal suturing performed with adjunctive application of gelatin-thrombin matrix (FloSeal®).
Group C - Suturing + Surgicel®	Experimental	Procedure: Suturing with Surgicel®Parenchymal suturing performed with adjunctive use of oxidized regenerated cellulose (Surgicel®).

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (5 listed)

Patients aged 18 years or older.
Diagnosed with localized renal mass (clinical stage T1a-T1b) suitable for partial nephrectomy.
Adequate preoperative renal function to undergo surgery.
Signed informed consent obtained prior to study enrollment.
Undergoing open, laparoscopic, or robotic partial nephrectomy performed by the same experienced surgeon.

Key exclusion criteria (8 listed)

Patients with solitary kidney or bilateral renal tumors.
History of previous renal surgery on the same kidney.
Evidence of metastatic disease or locally advanced (≥T2) renal tumors.
Coagulopathy, bleeding disorders, or ongoing anticoagulant therapy that cannot be discontinued.
Active urinary tract infection or systemic infection.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Standard Parenchymal SuturingStandard parenchymal suturing technique performed during partial nephrectomy without the use of adjunctive hemostatic materials. Serves as the control arm in the study.	Procedure or surgery	Group A - Suturing Only
Suturing with FloSeal®Partial nephrectomy performed with parenchymal suturing combined with gelatin-thrombin matrix (FloSeal®) as an adjunctive hemostatic agent.	Procedure or surgery	Group B - Suturing + FloSeal®
Suturing with Surgicel®Partial nephrectomy performed with parenchymal suturing combined with oxidized regenerated cellulose (Surgicel®) as an adjunctive hemostatic agent.	Procedure or surgery	Group C - Suturing + Surgicel®

Primary outcome

Incidence of clinically significant postoperative hemorrhage requiring blood transfusion
Time frame: From postoperative Day 0 through postoperative Day 30
Presence of postoperative bleeding requiring blood transfusion, radiologic, or surgical intervention, recorded according to standardized clinical criteria.
Incidence of postoperative urinary leakage or fistula
Time frame: From postoperative Day 0 through postoperative Day 30
Detection of urinary leakage based on drain creatinine measurement or radiologic evidence of fistula following partial nephrectomy.
Rate of positive surgical margins
Time frame: At pathological assessment (Day of surgery)
Pathologic assessment of surgical margins on resected tumor specimens to evaluate oncologic safety.

4 secondary outcomes

Mean operative time and warm ischemia time
Time frame: Intraoperative (Day of surgery)
Estimated blood loss during surgery
Time frame: Intraoperative (Day of surgery)
Change in postoperative renal function (serum creatinine and eGFR)
Time frame: Preoperative (1 day before surgery) and postoperative Day 30
Postoperative hospital stay
Time frame: From postoperative Day 0 until discharge, assessed for up to 30 days.

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2025.
Results publication: PubMed 19683266Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, Russo P, Uzzo RG; Practice Guidelines Committee of the American Urological Association. Guideline for management of the clinical T1 renal mass. J Urol. 2009 Oct;182(4):1271-9. doi: 10.1016/j.juro.2009.07.004. Epub 2009 Aug 14. No abstract available.
Results publication: PubMed 35407375Di Maida F, Campi R, Lane BR, De Cobelli O, Sanguedolce F, Hatzichristodoulou G, Antonelli A, Grosso AA, Noyes S, Rodriguez-Faba O, Keeley FX, Langenhuijsen J, Musi G, Klatte T, Roscigno M, Akdogan B, Furlan M, Simeone C, Karakoyunlu N, Marszalek M, Capitanio U, Volpe A, Brookman-May S, Gschwend JE, Smaldone MC, Uzzo RG, Kutikov A, Minervini A, Sib International Consortium. Predictors of Positive Surgical Margins after Robot-Assisted Partial Nephrectomy for Localized Renal Tumors: Insights from a Large Multicenter International Prospective Observational Project (The Surface-Intermediate-Base Margin Score Consortium). J Clin Med. 2022 Mar 23;11(7):1765. doi: 10.3390/jcm11071765.
Results publication: PubMed 35346519Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, Fernandez-Pello S, Giles RH, Hofmann F, Hora M, Klatte T, Kuusk T, Lam TB, Marconi L, Powles T, Tahbaz R, Volpe A, Bex A. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022 Oct;82(4):399-410. doi: 10.1016/j.eururo.2022.03.006. Epub 2022 Mar 26.
Results publication: PubMed 25615258Zargar H, Khalifeh A, Autorino R, Akca O, Brandao LF, Laydner H, Krishnan J, Samarasekera D, Haber GP, Stein RJ, Kaouk JH. Urine leak in minimally invasive partial nephrectomy: analysis of risk factors and role of intraoperative ureteral catheterization. Int Braz J Urol. 2014 Nov-Dec;40(6):763-71. doi: 10.1590/S1677-5538.IBJU.2014.06.07.
Results publication: PubMed 27431979Erlich T, Abu-Ghanem Y, Ramon J, Mor Y, Rosenzweig B, Dotan Z. Postoperative Urinary Leakage Following Partial Nephrectomy for Renal Mass: Risk Factors and a Proposed Algorithm for the Diagnosis and Management. Scand J Surg. 2017 Jun;106(2):139-144. doi: 10.1177/1457496916659225. Epub 2016 Jul 18.
Results publication: PubMed 39470887Kola O, Smigelski M, Nagpal S, Gogaj R, Taneja SS, Wysock JS, Huang WC. Urine leak and vascular complications following robotic partial nephrectomy: a contemporary single-center experience. J Robot Surg. 2024 Oct 29;18(1):387. doi: 10.1007/s11701-024-02096-1.
Results publication: PubMed 27279548Maurice MJ, Ramirez D, Kara O, Malkoc E, Nelson RJ, Caputo PA, Kaouk JH. Omission of Hemostatic Agents During Robotic Partial Nephrectomy Does Not Increase Postoperative Bleeding Risk. J Endourol. 2016 Aug;30(8):877-83. doi: 10.1089/end.2016.0192.
Results publication: PubMed 31040606Basu S, Khan IA, Das RK, Dey RK, Khan D, Agarwal V. RENAL nephrometry score: Predicting perioperative outcomes following open partial nephrectomy. Urol Ann. 2019 Apr-Jun;11(2):187-192. doi: 10.4103/UA.UA_93_18.
Results publication: PubMed 27572274Abu-Ghanem Y, Dotan Z, Kaver I, Zilberman DE, Ramon J. The use of Haemostatic Agents does not impact the rate of hemorrhagic complications in patients undergoing partial nephrectomy for renal masses. Sci Rep. 2016 Aug 30;6:32376. doi: 10.1038/srep32376.
Results publication: PubMed 31258357Aykan S, Temiz MZ, Ulus I, Yilmaz M, Gonultas S, Suzan S, Semercioz A, Muslumanoglu AY. The Use of Three Different Hemostatic Agents during Laparoscopic Partial Nephrectomy: A Comparison of Surgical and Early Renal Functional Outcomes. Eurasian J Med. 2019 Jun;51(2):160-164. doi: 10.5152/eurasianjmed.2018.18293.
Results publication: PubMed 30613663Veccia A, Autorino R. Is there a relation between preserved renal function and oncological outcomes in patients undergoing partial nephrectomy for renal cell carcinoma? Ann Transl Med. 2018 Nov;6(Suppl 1):S88. doi: 10.21037/atm.2018.11.01. No abstract available.
Results publication: PubMed 29277887Tonyali S, Koni A, Yazici S, Bilen CY. The Safety and Efficacy of Adjuvant Hemostatic Agents During Laparoscopic Nephron-Sparing Surgery: Comparison of Tachosil and Floseal Versus No Hemostatic Agents. Urol J. 2017 Jan 23;15(1):21-25. doi: 10.22037/uj.v0i0.4090.
Individual participant dataSharing planned: Undecided

Related trials for Partial Nephrectomy

Active, not recruitingObservational study
A Study to Understand the Utility of the Force Feedback Instruments in Robotic Procedures Using da Vinci 5 Robot
Hernia, Inguinal, Hernia, Ventral
Active, not recruitingObservational study
Multimodal Prediction of Postoperative Prognosis After Partial Nephrectomy for Endophytic Renal Cell Carcinoma
Renal Cell Carcinoma, Kidney Neoplasms
Active, not recruitingObservational study
Analysis of Predictive Factors for Urinary Leakage After Partial Nephrectomy for Renal Hilum Tumors
Partial Nephrectomy, Renal Hilum Tumors
Recruiting
Prospective Study on the Safety and Efficacy of Robot-Assisted Laparoscopic Partial Nephrectomy With Renal Artery Off-Clamp in the Treatment of cT1 Renal Tumors
RCC, Renal Cell Cancer, Partial Nephrectomy
Recruiting
Robot-assisted Laparoscopic Partial Nephrectomy Via the Extraperitoneal Approach in the Prone Position Versus the Lateral Position
Renal Tumor, Prone Position

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of clinically significant postoperative hemorrhage requiring blood transfusion (time frame: From postoperative Day 0 through postoperative Day 30). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07232927, which also lists 22 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2025; AzTrials last refreshed its copy on 3 Nov 2026.